H eart failure (HF) with preserved ejection fraction (HFpEF) has traditionally been viewed as a form of hypertensive heart disease with increased left ventricular (LV) afterload ultimately leading to HFpEF. However, HFpEF patients typically have numerous other comorbidities. 1 Although the severity of LV remodeling and ventricular vascular dysfunction 2 and the rate of adverse outcomes 3 are greater in patients with HFpEF than in patients with comorbidities alone, some argue that HFpEF is not a distinct syndrome but rather a collection of comorbidities masquerading as HF.
See Article by Srivaratharajah et al
More recently, based on integrative physiological studies in human HFpEF, the biology of nitric oxide-cyclic guanosine monophosphate-protein kinase G signaling, and elegant studies of human HFpEF myocardium, Paulus and Tschope synthesized an alternate HFpEF pathophysiologic paradigm. 1 This paradigm postulates that multimorbidity creates a systemic proinflammatory milieu, coronary microvascular endothelial inflammation, and migration of inflammatory cells to the myocardium with production of proinflammatory cytokines, myocardial inflammation, and subsequent fibrosis. Further, they propose that microvascular endothelial inflammation promotes oxidative stress with generation of oxidative/nitrosative species, which limits myocardial nitric oxide-cyclic guanosine monophosphate-protein kinase G signaling by diminishing nitric oxide bioavailability and oxidizing downstream nitric oxide targets, thus promoting cardiomyocyte hypertrophy. Impaired protein kinase G activity and peroxynitrite-stimulated phosphatases are proposed to alter the phosphorylation status of proteins that influence myofiber relaxation and stiffness and, thus, further impair LV diastolic function.
This paradigm has sparked great interest in therapies that target impaired myocardial cyclic guanosine monophosphateprotein kinase G signaling in HFpEF. However, the Paulus paradigm has an important correlate in that an established consequence of coronary microvascular endothelial inflammation is impaired coronary microvascular endothelial function and ultimately coronary microvascular remodeling and rarefaction with decreased microvascular density (MVD). 4 The potential impact of diffuse microvascular endothelial inflammation on the functional and structural integrity of the microcirculation and the role that microcirculatory dysfunction itself may play in HFpEF pathophysiology are unclear. In this issue of Circulation: Heart Failure, Srivaratharajah et al 5 add to a small but growing body of literature, which suggests a role for microvascular dysfunction in the pathophysiology of HFpEF.
Coronary Vasculature in Health and Disease
Coronary arterial function is highly coordinated, 6,7 with flow regulated by shear stress and endothelial function (flow-mediated vasodilatation) in the epicardial arteries and prearterioles, myogenic tone in prearterioles and larger arterioles, and metabolic vasodilatation in the arterioles during increases in myocardial oxygen consumption. This coordinated network serves to match coronary blood flow with myocardial oxygen requirements.
Impaired microcirculatory function related to endothelial dysfunction is seen in patients with atherosclerotic risk factors. 6, 7 These comorbidities and coronary atherosclerosis are common in HFpEF. 2, 8, 9 Ultimately, perivascular fibrosis, microvascular remodeling, and microvascular rarefaction can further limit microcirculatory function. Such structural alterations are seen in myocardial diseases, including dilated and hypertrophic cardiomyopathies and LV hypertrophy related to hypertension or aortic stenosis. 6, 7 Despite documentation of coronary microvascular dysfunction in patients with atherosclerotic risk factors or significant myocardial disease, convincing evidence of a causal relationship between coronary microvascular dysfunction and myocardial ischemia has been difficult to establish. Epicardial coronary artery stenoses occur proximally in the coronary vascular network and cause global or large regional areas of ischemia with stress, increased O 2 extraction, and thus, increased transcardiac O 2 gradients with readily detectable contractile dysfunction and production of ischemic metabolites. 7, 10 In contrast, microvascular dysfunction occurs in the terminal vascular network and causes increased heterogeneity of flow and oxygen supply, which leads to functional shunting, localized hypoxia, reduced O 2 extraction, and decreases in the transcardiac O 2 gradient. The patchy impairment in perfusion may make detection of contractile abnormalities or production of ischemic metabolites using traditional techniques difficult. 7
Tools to Assess Coronary Microvascular Function
O 2 , and metabolite gradients and intracoronary infusion of endothelium-specific and nonspecific vasodilators to assess the microvasculature. 6, 7, [10] [11] [12] Myocardial blood flow indexed to LV mass and corrected for demand (typically using the rate pressure product) can be measured noninvasively with cardiac positron emission tomography (PET) using a variety of tracers. 13 Alternatively, cardiac magnetic resonance phase-contrast imaging of the coronary sinus can measure myocardial (coronary sinus) blood flow. 14 By either method, myocardial flow reserve (MFR) can be assessed as the ratio of maximal hyperemic to resting myocardial blood flow. Maximal hyperemic myocardial blood flow is assessed by the administration of intravenous vasodilators, typically adenosine, but dipyridimole or ATP is also used. In the absence of epicardial coronary stenosis, adenosine-induced hyperemic myocardial blood flow response (and MFR) represents global microvascular function and cannot discriminate between endothelial dysfunction, impaired myogenic responsiveness, or altered microvascular structure. 13
Coronary Microvascular Dysfunction and HFpEF
Numerous studies have documented impaired systolic and diastolic cardiac reserve in HFpEF, and ischemia due to coronary microvascular dysfunction could contribute to impaired reserve function. 15 Angina is common in HFpEF but equally common in patients with or without epicardial coronary artery disease. 8 Moreover, energetic reserve deficit (reduced cardiac creatine phosphate/adenosine triphosphate ratio) has been reported in HFpEF without epicardial coronary artery disease. 16 To date, only a few studies have assessed coronary microvascular dysfunction in HFpEF. We studied coronary MVD in autopsy specimens from 124 HFpEF subjects and found that MVD was decreased in HFpEF relative to 104 sex-and age-appropriate controls who died of noncardiac causes ( Figure 1 ). 9 Further, the severity of microvascular rarefaction was associated with the severity of myocardial fibrosis, consistent with the proposed relationship between microvascular endothelial inflammation, myocardial fibrosis, and microvascular rarefaction. Importantly, MVD was reduced independently of epicardial coronary artery atherosclerosis or history of hypertension.
van Empel performed assessment of rest and exercise transcardiac O 2 gradients, invasive hemodynamics, and echocardiography in 9 HFpEF patients without coronary disease and hypertensive (n=7) and healthy (n=12) controls. 11 The increase in the transcardiac O 2 gradient with stress was blunted in HFpEF as compared with either control group, consistent with impaired O 2 extraction and microcirculatory dysfunction as outlined earlier. 7 Further, the severity of stress-induced diastolic dysfunction correlated with the severity of impairment in O 2 extraction.
Recently, Kato et al reported a study which prospectively enrolled 25 HFpEF patients (European Society of Cardiology criteria), 13 non-HF controls with hypertensive LV hypertrophy, and 18 healthy non-HF controls. 17 All participants underwent brain natriuretic peptide measurement, echo, cardiac magnetic resonance, and computed tomographic imaging to exclude epicardial coronary artery disease. MFR was assessed using cardiac magnetic resonance imaging and ATP infusion. MFR was lower in HFpEF than either control population (Figure 2 ). HFpEF patients (109 g/m 2 ) had higher LV mass index than normal controls (60 g/m 2 ), but hypertensive controls (132 g/m 2 ) had significantly higher LV mass than HFpEF patients, suggesting that hypertension and LV hypertrophy related microvascular dysfunction does not solely account for the reduction in MFR observed in HFpEF. HFpEF patients with lower MFR had higher brain natriuretic peptide levels.
Srivaratharajah et al now confirm these previous findings using a convenience sample of patients referred to cardiac PET for evaluation of clinically suspected coronary artery disease because of symptoms (chest pain, dyspnea, or arrhythmia), high risk factor profile, or positive stress tests. 5 Over 1000 PET-referred patients had a normal ejection fraction and no PET evidence of epicardial coronary artery disease. Of these, 78 were retrospectively identified to have a previous diagnosis of HFpEF by chart review and were compared with 112 normotensive and 186 hypertensive controls. MFR was assessed by Rb-82 PET and dipyridamole infusion. MFR was lower in HFpEF patients than either control, and among HFpEF patients, MFR was lower in HFpEF patients with more severe symptoms. Further, MFR was lower in HFpEF patients after adjusting for pertinent covariates. Only a small number of HFpEF patients had epicardial coronary artery stenosis excluded by angiography, and MFR was similar in those patients as compared with the other HFpEF patients. Although HFpEF patients had a previous clinical diagnosis of HF, the majority (54%) were asymptomatic as assessed by New York Heart Association class I symptoms. Presumably, New York Heart Association status was collected routinely as part of the clinical PET referral process because it was available in all patients regardless of HF history and, thus, may or may not accurately assess HF severity. If accurate, the finding of reduced MFR in these patients with mild or early HFpEF is notable. Echocardiograms were available in 50% of HFpEF patients and ≈25% of controls, and the severity of reduction in MFR correlated with severity of resting diastolic dysfunction.
The systemic nature of the comorbidity-related proinflammatory milieu suggests that the skeletal muscle vascular beds would also be affected. 18 Impaired skeletal muscle oxygen extraction and utilization contribute to exercise intolerance in HFpEF. 18, 19 Reduced skeletal muscle MVD has been demonstrated in HFpEF 18 and correlates with the severity of impairment in peak O 2 consumption.
Is Coronary Microvascular Dysfunction Sufficient to Cause HFpEF?
Although the studies above in typical HFpEF patients document an association between coronary microvascular dysfunction and the presence of HFpEF, microvascular dysfunction is not specific to HFpEF, 6, 7 and associations do not prove causality. However, there is evidence to suggest that microvascular inflammation and dysfunction can cause diastolic dysfunction and HFpEF in the absence of hypertensive remodeling or other cardiac abnormalities. Tschope et al studied young patients (mean age 43) with a clinical diagnosis of HFpEF, invasively confirmed diastolic dysfunction, and none of the usual comorbidities associated with HFpEF. 12 Cardiotropic viral genomes were assessed in endomyocardial biopsy samples. There was a high prevalence of parvovirus B19 infection, sometimes in association with human herpes virus 6. Both these viruses specifically infect vascular endothelial cells and are not known to infect cardiomyocytes, suggesting that microvascular endothelial inflammation related to viral infection is sufficient to cause diastolic dysfunction and clinical HFpEF. Indeed, virus-positive patients had a high rate of endothelial dysfunction assessed by intracoronary Doppler flow-velocity catheters and acetylcholine infusion, although global microvascular function and MVD were not assessed.
Cardiomyocytes are resistant to ionizing radiation, and lower dose cardiac radiation exposure selectively induces microvascular endothelial damage with subsequent microvascular inflammation, microvascular rarefaction, myocardial inflammation, oxidative stress, and fibrosis in animal models. 20 Further study of animal models of cardiac radiation exposure and older women undergoing breast cancer radiotherapy may provide insight to a specific link between coronary microvascular dysfunction and HFpEF.
Conclusions
Further studies carefully assessing the degree of microvascular impairment across the spectrum of HFpEF clinical phenotypes and severities are needed. The functional significance of microvascular impairment in terms of its impact on myocardial oxygen extraction, energetic reserve, and myocardial reserve function needs to be determined and the role of functional versus structural microvascular abnormalities defined. Such studies are needed to determine in which patients and how microvascular function could be specifically targeted for therapeutic intervention in HFpEF. 
